Patents Assigned to ZymoGenetics, Inc.
  • Materials and methods for preparing dimeric growth factors
    Patent number: 7556941
    Abstract: Proteins consisting of, from amino to carboxyl terminus, a first PDGF-D growth factor domain polypeptide, a linker polypeptide, and a second PDGF-D growth factor domain polypeptide, and materials and methods for making the proteins are disclosed. Each of the first and second PDGF-D growth factor domain polypeptides consists of a sequence of amino acid residues as shown in SEQ ID NO: 2 or SEQ ID NO: 4 from amino acid x to amino acid y, wherein x is an integer from 246 to 258, inclusive, and y is an integer from 365-370, inclusive. The linker polypeptide consists of from 11-40 amino acid residues. The proteins can be used to stimulate the production of bone and/or connective tissue in both humans and non-human animals.
    Type: Grant
    Filed: October 17, 2006
    Date of Patent: July 7, 2009
    Assignee: ZymoGenetics, Inc.
    Inventors: Brian A. Fox, Margaret Dow Moore, Kristine M. Swiderek, Carl W. Birks
  • IL-17A AND IL-17F ANTAGONISTS AND METHODS OF USING THE SAME
    Publication number: 20090155271
    Abstract: The present invention relates antagonists of IL-17A and IL-17F. The antagonists of the invention are based on IL-17RC alone or on both IL-17RC and IL-17RA (“IL-17RC/IL-17RA”). Such antagonists serve to block, inhibit, reduce, antagonize or neutralize the activity of IL-17F, IL-17A, or both IL-17A and IL-17F. IL-17A and IL-17F are cytokines that are involved in inflammatory processes and human disease. IL-17RA is a receptor for IL-17A and IL-17RC is a common receptor for both IL-17A and IL-17F. The present invention includes soluble IL-17A and IL-17F anatagonists, as well as methods for using the same.
    Type: Application
    Filed: February 12, 2009
    Publication date: June 18, 2009
    Applicant: ZYMOGENETICS, INC.
    Inventors: STEVEN D. LEVIN, MARK W. RIXON, ZEREN GAO
  • Method of treating fibrosis
    Patent number: 7547437
    Abstract: Materials and methods for treating fibrosis in a mammal are disclosed. The methods comprise administering to a mammal a composition comprising a therapeutically effective amount of a zvegf3 antagonist in combination with a pharmaceutically acceptable delivery vehicle. Zvegf3 antagonists include anti-zvegf3 antibodies, mitogenically inactive receptor-binding zvegf3 variant polypeptides, and inhibitory polynucleotides. Within one embodiment of the invention the fibrosis is liver fibrosis.
    Type: Grant
    Filed: September 6, 2007
    Date of Patent: June 16, 2009
    Assignee: ZymoGenetics, Inc.
    Inventor: Debra G. Gilbertson
  • Human kunitz-type inhibitors and methods relating thereto
    Patent number: 7541449
    Abstract: The present invention provides isolated DNA molecules comprising a DNA segment encoding novel human Kunitz-type inhibitors. Also provided are DNA constructs comprising a first DNA segment encoding a novel human Kunitz-type inhibitor wherein said first DNA segment is operably linked to additional DNA segments required for the expression for the first DNA segment, as well as host cells containing such DNA constructs and methods for producing proteins from the host cells.
    Type: Grant
    Filed: January 4, 2007
    Date of Patent: June 2, 2009
    Assignees: STC.UNM, Zymogenetics, Inc.
    Inventors: Cindy A. Sprecher, Walt Kisiel, Donald C. Foster
  • Anti-IL-22RA antibodies and binding partners and methods of using in inflammation
    Patent number: 7537761
    Abstract: The present invention relates to blocking, inhibiting, reduceing, antagonizing or neutralizing the activity of IL-22, IL-20, or both IL-20 and IL-22 polypeptide molecules. IL-20 and IL-22 are cytokines that are involved in inflammatory processes and human disease. IL-22RA (zcytor11) is a common receptor for IL-20 and IL-22. The present invention includes anti-IL-22RA antibodies and binding partners, as well as methods for antagonizing IL-22 or both IL-20 and IL-22 using such antibodies and binding partners.
    Type: Grant
    Filed: October 21, 2005
    Date of Patent: May 26, 2009
    Assignee: ZymoGenetics, Inc.
    Inventors: Wenfeng Xu, Wayne R. Kindsvogel, Yasmin A. Chandrasekher, Stacey R. Dillon, Joyce M. Lehner, Anthony W. Siadak, Pallavur V. Sivakumar, Margaret Dow Moore
  • Method for detecting cancer using an antibody to Zcytor16
    Patent number: 7534575
    Abstract: Cytokines and their receptors have proven usefulness in both basic research and as therapeutics. The present invention provides a new human cytokine receptor designated as “Zcytor16.
    Type: Grant
    Filed: February 1, 2007
    Date of Patent: May 19, 2009
    Assignee: ZymoGenetics, Inc.
    Inventors: Scott R. Presnell, Wenfeng Xu, Wayne Kindsvogel, Zhi Chen
  • Methods of detecting or diagnosing inflammatory bowel disease using prokineticin polynucleotides
    Patent number: 7531311
    Abstract: The present invention provides methods of using Zven1 and Zven2 polypeptides to increase chemokine production. The present invention also provides methods of using antagonists to Zven1 and Zven2 to treat inflammation in the intestine.
    Type: Grant
    Filed: October 19, 2006
    Date of Patent: May 12, 2009
    Assignee: Zymogenetics, Inc.
    Inventors: Penny J. Thompson, Paul O. Sheppard
  • IL-31 monoclonal antibodies
    Patent number: 7531637
    Abstract: The present invention relates to methods of treating pruritic diseases, including but not limited to Contact dermatitis, Atopic Dermatitis, Drug induced delayed type cutaneous allergic reactions, Toxic epidermal necrolysis, Cutaneous T cell Lymphoma, Bullous pemphigoid, Alopecia wereata, Vitiligo, Acne Rosacea, Prurigo nodularis, Scleroderma, Herpes simplex virus, or combination thereof by administering IL-31 monoclonal antibodies. The invention further provides the hybridomas that generate the monoclonal antibodies.
    Type: Grant
    Filed: May 8, 2006
    Date of Patent: May 12, 2009
    Assignee: ZymoGenetics, Inc.
    Inventors: Anthony W. Siadak, Janine Bilsborough, Shirley Rene
  • Antibodies to murine zcytor17 ligand
    Patent number: 7531636
    Abstract: The present invention relates to zcytor17lig polynucleotide, polypeptide and anti-zcytor17 antibody molecules. The zcytor17lig is a novel cytokine. The polypeptides may be used within methods for stimulating the immune system, and proliferation and/or development of hematopoietic cells in vitro and in vivo. The present invention also includes methods for producing the protein, uses therefor and antibodies thereto.
    Type: Grant
    Filed: December 19, 2006
    Date of Patent: May 12, 2009
    Assignee: ZymoGenetics, Inc.
    Inventors: Cindy A. Sprecher, Joseph L. Kuijper, Maria M. Dasovich, Francis J. Grant, Angela K. Hammond, Jane A. Gross, Rolf E. Kuestner
  • MASS SPECTROMETRY-BASED QUANTITATIVE ASSAY FOR DETERMINING ABUNDANCE OF MOLECULAR SPECIES IN A COMPOSITION
    Publication number: 20090101809
    Abstract: Provided herein are quantitative LC-MS methods is aimed at identifying and quantifying the molecular species in a composition. Additionally provided are compositions comprising one or more molecular species.
    Type: Application
    Filed: September 5, 2008
    Publication date: April 23, 2009
    Applicant: ZYMOGENETICS, INC.
    Inventor: Sibylle M. Wilbert
  • Cytokine receptor zcytor17
    Patent number: 7521537
    Abstract: Novel polypeptides, polynucleotides encoding the polypeptides, and related compositions and methods are disclosed for zcytor17, a novel cytokine receptor. The polypeptides may be used within methods for detecting ligands that stimulate the proliferation and/or development of hematopoietic, lymphoid and myeloid cells in vitro and in vivo. Ligand-binding receptor polypeptides can also be used to block ligand activity in vitro and in vivo. The polynucleotides encoding zcytor17, are located on chromosome 5, and can be used to identify a region of the genome associated with human disease states. The present invention also includes methods for producing the protein, uses therefor and antibodies thereto.
    Type: Grant
    Filed: October 20, 2006
    Date of Patent: April 21, 2009
    Assignee: ZymoGenetics, Inc.
    Inventors: Cindy A. Sprecher, Scott R. Presnell, Zeren Gao, Theodore E. Whitmore, Joseph L. Kuijper, Mark F. Maurer
  • Vectors encoding interleukin-17 receptor homologue
    Patent number: 7521208
    Abstract: Cytokines and their receptors have proven usefulness in both basic research and as therapeutics. The present invention provides a new human cytokine receptor designated as “Zcytor14.
    Type: Grant
    Filed: October 2, 2006
    Date of Patent: April 21, 2009
    Assignee: ZymoGenetics, Inc.
    Inventors: Scott R. Presnell, Steven K. Burkhead, Sarah L. Pownder
  • Interleukin-17 receptor homologue
    Patent number: 7517958
    Abstract: Cytokines and their receptors have proven usefulness in both basic research and as therapeutics. The present invention provides a new human cytokine receptor designated as “Zcytor14.
    Type: Grant
    Filed: October 2, 2006
    Date of Patent: April 14, 2009
    Assignee: ZymoGenetics, Inc.
    Inventors: Scott R. Presnell, Steven K. Burkhead, Sarah L. Pownder
  • Methods of antagonizing signal transduction in dorsal root ganglion cells with IL-31 antagonists
    Patent number: 7514077
    Abstract: Use of antagonists to IL-31 are used to treat inflammation and pain by inhibiting, preventing, reducing, minimizing, limiting or minimizing stimulation in neuronal tissues. Such antagonists include antibodies and fragments, derivative, or variants thereof. Symptoms such as pain, tingle, sensitization, tickle associated with neuropathies are ameliorated.
    Type: Grant
    Filed: January 10, 2007
    Date of Patent: April 7, 2009
    Assignee: ZymoGenetics, Inc.
    Inventors: Yue Yao, Janine Bilsborough
  • Homogeneous preparations of IL-28A cysteine mutants
    Patent number: 7514536
    Abstract: Homogeneous preparations of IL-28A, IL-28B, and IL-29 have been produced by mutating one or more of the cysteine residues in the polynucleotide sequences encoding the mature proteins. The cysteine mutant proteins can be shown to either bind to their cognate receptor or exhibit biological activity. One type of biological activity that is shown is an antiviral activity.
    Type: Grant
    Filed: October 17, 2006
    Date of Patent: April 7, 2009
    Assignee: ZymoGenetics, Inc.
    Inventors: Lowell J. Brady, Kevin M. Klucher, Chung Chan, Dennis L. Dong, Hong Y. Liu, Paul O. Sheppard, Thomas R. Bukowski
  • Growth factor homolog zvegf4
    Patent number: 7514238
    Abstract: Polypeptide growth factors, methods of making them, polynucleotides encoding them, antibodies to them, and methods of using them are disclosed. The polypeptides comprise an amino acid segment that is at least 70% identical to residues 52-179 of SEQ ID NO:2 or residues 258-370 of SEQ ID NO:2. Multimers of the polypeptides are also disclosed. The polypeptides, multimeric proteins, and polynucleotides can be used in the study and regulation of cell and tissue development, as components of cell culture media, and as diagnostic agents.
    Type: Grant
    Filed: October 17, 2006
    Date of Patent: April 7, 2009
    Assignee: ZymoGenetics, Inc.
    Inventors: Teresa Gilbert, Charles E. Hart, Paul O. Sheppard
  • Ztnfr14, a tumor necrosis factor receptor
    Patent number: 7507580
    Abstract: Novel tumor necrosis factor receptor (TNFR) polypeptides, polynucleotides encoding the polypeptides, antibodies and related compositions and methods are disclosed. The polypeptides may be used for detecting ligand, as well as agonists and antagonists. The polypeptides, polynucleotides and antibodies may also be used in methods that modulate tumor growth, metastasis, and immunity such as separating resting from stimulated immune cells.
    Type: Grant
    Filed: October 18, 2004
    Date of Patent: March 24, 2009
    Assignee: ZymoGenetics, Inc.
    Inventors: Brian A. Fox, James L. Holloway, Paul O. Sheppard, Stacey R. Dillon
  • Murine ZCYTOR17 ligand polypeptides
    Patent number: 7507795
    Abstract: The present invention relates to zcytor17lig polynucleotide, polypeptide and anti-zcytor17 antibody molecules. The zcytor17lig is a novel cytokine. The polypeptides may be used within methods for stimulating the immune system, and proliferation and/or development of hematopoietic cells in vitro and in vivo. The present invention also includes methods for producing the protein, uses therefor and antibodies thereto.
    Type: Grant
    Filed: December 13, 2006
    Date of Patent: March 24, 2009
    Assignee: ZymoGenetics, Inc.
    Inventors: Cindy A. Sprecher, Joseph L. Kuijper, Maria M. Dasovich, Francis J. Grant, Jane A. Gross, Angela K. Hammond, Rolf E. Kuestner
  • TACI-immunoglobulin fusion proteins
    Patent number: 7501497
    Abstract: Molecules that interfere with the binding of a tumor necrosis factor receptor with its ligand, such as a soluble receptor, have proven usefulness in both basic research and as therapeutics. The present invention provides improved soluble transmembrane activator and calcium modulator and cyclophilin ligand-interactor (TACI) receptors.
    Type: Grant
    Filed: October 3, 2005
    Date of Patent: March 10, 2009
    Assignee: ZymoGenetics, Inc.
    Inventors: Mark W. Rixon, Jane A. Gross
  • Nucleic acid encoding a human interferon-like protein Zcyto21
    Patent number: 7498154
    Abstract: The present invention relates to polynucleotide and polypeptide molecules for Zcyto21, an interferon-like protein, which is most closely related to interferon-? at the amino acid sequence level. The present invention also includes antibodies to the Zcyto21 polypeptides, and methods of using the polynucleotides and polypeptides.
    Type: Grant
    Filed: October 26, 2007
    Date of Patent: March 3, 2009
    Assignee: ZymoGenetics, Inc.
    Inventors: Paul O. Sheppard, Scott R. Presnell, Brian A. Fox, Teresa Gilbert, Betty A. Haldeman, Francis J. Grant